Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.67 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3358867 | 0.99 | HTR2A (0.66) | HTR2ACTSDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15407540 | 0.88 | CTSD (0.52) | HTR2ACTSDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1976152 | 0.88 | CTSD (0.52) | HTR2ACTSDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1976155 | 0.88 | CTSD (0.52) | HTR2ACTSDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1976153 | 0.88 | CTSD (0.52) | HTR2ACTSDSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3357777 | 0.86 | CTSD (0.51) | HTR2ACTSDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30828745 | 0.85 | SIGMAR1 (0.54) | HTR2ASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30828771 | 0.85 | SIGMAR1 (0.54) | HTR2ASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30828750 | 0.85 | SIGMAR1 (0.54) | HTR2ASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30828775 | 0.85 | SIGMAR1 (0.54) | HTR2ASLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB | 2012-10-25 | — | — | US | disclosed |
| EP-2121702-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | NQO2, SDHA, NDUFS5 | HTR2A 1487/4885CTSD 1716/4885SLC6A2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.